Objective To observe the effect of the self-made traditional Chinese medicine combined with brufen in treatment of cervical spondylosis. Methods 170 cases were divided into the treatment group(85 cases) and the control group(85 cases) randomly. The control group was treated with brufen. Patients in treatment group received routine treatment plus the self-made traditional Chinese medicine. After the treatment, the curative effect, aches and coma were analyzed. Results The total effective rate was 94. 1% in treatment group but 84. 7% in control group.Difference between the two groups had statistical significance( x2 = 3.997,P ＜ 0. 05). The integrate of 1 ahes and coma were ( 7. 8 ± 2. 4), (9. 4 ± 2. 1 ) marks and ( 2. 5 ± 0. 6), (3. 1 ± 0. 9) respectively, it was lower than before treatment(11.9 ±2.3) ,(12.3 ±2.9) marks and (5.6 ± 1.4) ,(5.3 ± 1.2) marks. Aches and coma showed a great difference after treatment from those before treatment( t = 34. 641、6. 159、6. 173、6. 080,all P ＜0. 05 ). Aches and coma were lower then those of control group(t =9. 283、3. 464,all P ＜0. 05). No severe adverse reaction occurred in two groups. Conclusion The self-made traditional Chinese medicine combined with brufen is effective to treat aches and coma in cervical spondylosis. The method was feasible for treat aches and coma in cervical spondylosis.

OBJECTIVE To investigate the effects of vorinostat （SAHA） on immune function in rats with Sjögren syndrome （SS） by regulating interleukin-6（IL-6）/signal transducer and activator of transcription 3 （STAT3）. METHODS SS model was constructed by complete/incomplete Freund’s adjuvant immune induction， and the rats with successful modeling were divided into model group， SAHA low-dose， medium-dose and high-dose groups （25， 50， 100 mg/kg）， and high-dose SAHA+IL-6/STAT3 signaling pathway activator group （100 mg/kg SAHA+0.05 mg/kg recombinant IL-6 protein）， with 10 rats in each group. Another 10 healthy rats were collected as the control group. Rats in each group were intraperitoneally injected with the corresponding drug/ normal saline， once a day， for consecutive 2 weeks. The water intake （1 d） and saliva flow （10 min） of rats in each group were measured， and the spleen index and submandibular gland index were measured； pathological changes in submandibular gland tissue were observed. The serum levels of interferon-γ （IFN-γ）， IL-17 and IL-10 were detected， and the differentiation of T lymphocyte subgroups in peripheral blood was also detected； the expressions of IL-6/STAT3 signaling pathway-related proteins in submandibular gland were detected. RESULTS Compared with the control group， obvious focal infiltration of lymphocytes was observed in the submandibular gland tissue of rats in the model group， and the number of acinar cells was decreased significantly； the water intake， spleen index， pathological score of submandibular gland， serum levels of IFN-γ and IL-17， and the ratios of helper T cell 1 （Th1） and Th17 as well as the protein expression of IL-6 and the protein phosphorylation of STAT3 in submandibular gland were increased obviously （P＜0.05）； the saliva flow， submandibular gland index， serum level of IL-10 and regulatory T cell （Treg） ratio were obviously decreased （P＜0.05）. Compared with the model group， the damage to the submandibular gland in SAHA groups was relieved， the quantitative indexes were obviously improved in dose-dependent manner （P＜0.05）； recombinant IL-6 protein could reverse the improvement effect of SAHA on above indexes of rats （P＜0.05）. CONCLUSIONS SAHA can relieve the injury of submandibular gland and regulate its immune function in SS rats， which may be related to inhibiting the IL-6/STAT3 signaling pathway.

Objective To examine the correlation of urinary podocyte number and giomerular podocalyxin expression with clinicopathology in IgA nephropathy(IgAN)patients. Methods Morning urinary specimens(100 ml)3 days before renal biopsy from 50 patients with IgAN diagnosed by renal biopsy and from 20 healthy volunteers as control were collected. After centrifugation, 300 μI sediment was used for smear. Immunohistochemical staining with monoclonal anti-podocalyxin antibody was performed to detect urinary podocytes and the number of podocyte was counted under optical microscope. Computer image analysis system was used to examine glomerular PCX expression. Renal pathology and classification were investigated based on Lee's grading and Katafuchi semi-quantitative integration method. Relevance analysis was carried out on urinary podocyte number, glomerular PCX expression with pathological score and clinical data. Results The amount of urinary podocytes in IgAN was obviously higher than that in healthy controls(P<0.01). Significant differences were found in multiple comparison of the median of urinary podocytes among Lee's grade groups. I - II group was lower as compared to Ⅲ , Ⅳ, Ⅴ groups(all P<0.05). Ⅲ group was lower as compared to V group(P<0.05). The positive rate of urinary podocyte was the highest in Ⅳ and V groups(100%), while the lowest in Ⅰ - Ⅱ group(55%). Glomerular PCX expression in IgAN decreased with the aggravation of renal pathology. Significant differences were found in multiple comparison of the glomerular PCX expression with the pathological score. Lee's Ⅰ - Ⅱ group was higher as compared to Ⅲ, Ⅳ, Ⅴ groups(all P<0.05). Ⅳ and Ⅳ groups were higher as compared to V group(P<0.05). In IgAN, urinary podocyte excretion was negatively correlated with glomerular PCX expression(r=-0.702, P<0.01), positively correlated with 24-hour urinary protein(r=0.465, P<0.01)and positively correlated with glomerular and tubular scores(r=0.233, 0.307, P<0.05). Glomerular PCX expression was negatively correlated with 24-hour urinary protein(r=-0.367,P<0.05)and negatively correlated with glomerular and tubular scores(r =-0.560, -0.377, P <0.05). Conclusions Injury and desquamation of glomerular podocytes may involve in the development of IgAN. The number of urinary podocyte can reflect the loss of podocytes in renal tissue, which may be used as a marker of disease progression of IgAN.

【Objective】 To explore the plasma-activated medium (PAM) produced by low temperature plasma (LTP) on the proliferation and angiogenesis of human umbilical vein endothelial cells (HUVECs) so as to provide theoretical basis for the future use of PAM to promote wound healing and inhibit tumor angiogenesis. 【Methods】 HUVECs were selected as the in vitro research model. The PAM-containing medium after LTP treatment for different time points (0 s, 15 s, 30 s, 45 s, 60 s, and 75 s) was used for intervention. The influence of PAM on HUVECs viability was assessed using the MTT assay and cell cycle analysis. The effects of PAM on angiogenesis were examined through angiogenesis experiments. Intracellular levels of reactive oxygen species (ROS) were measured using fluorescence probes. A melanoma mouse model was established, and CD31 expression was detected by immunohistochemistry. 【Results】 As the treatment time increased, the intracellular levels of ROS also elevated. PAM derived from LTP exhibited a bidirectional effect on angiogenesis in HUVECs. Compared to the control group (0 s), low-dose treatments (15 s and 30 s) enhanced HUVECs viability, while high-dose treatments (45 s, 60 s, and 75 s) significantly decreased cell viability (P<0.05). The proportion of HUVECs in the S phase was significantly increased in the PAM-15 s and PAM-30 s groups, but markedly decreased in the PAM-45 s, PAM-60 s, and PAM-75 s groups, with statistically significant differences (P<0.05). The HUVECs tube formation ability was enhanced in the 15 s and 30 s PAM groups, but diminished in the PAM-45 s, PAM-60 s, and PAM-75 s groups, characterized by the decreased numbers of vascular nodes, intersections, meshes, and branching points (P<0.05). After PAM treatment in the melanoma mouse model, the control group exhibited widespread distribution of CD31 in tumor tissue, while the PAM-5 min and PAM-10 min groups displayed reduced distribution of CD31. 【Conclusion】 Short-term exposure to PAM enhances HUVECs proliferation and angiogenesis, whereas prolonged exposure suppresses cell viability and inhibits angiogenesis.

Objective: To study the non/hypo-response to hepatitis B vaccination in HIV-infected patients, identify the influencing factors and provide evidence for the development of hepatitis B prevention and control strategies and measures for special population. Methods: On the basis of the randomized controlled trial of 20 µg hepatitis B vaccine immunization at 0-1-6 month, 0-1-2-6 month and 60 µg hepatitis B vaccine immunization at 0-1-2-6 month, the HIV-infected patients who completed one-month follow-up after the full course vaccination were selected as study subjects. Quantification of antibody to hepatitis B surface antigen (anti-HBs) in serum samples was performed by using chemiluminescent microparticle immunoassay (CMIA) and demographic characteristics, disease history, HIV infection and treatment status of the study subjects were collected. Statistical analysis was conducted by χ² test, t test, unconditional logistic regression and interaction analyses. Results: The non/hypo-response rates to hepatitis B vaccination were 34.65% (35/101), 24.49% (24/98) and 10.99% (10/91) in 20 µg group at 0-1-6 month or 0-1-2-6 month and 60 µg group at 0-1-2-6 month (P<0.001), respectively. Logistic regression analysis showed that after controlling for confounding factors, the risk for non/hypo-response was 0.22 times higher in HIV-infected patients receiving 60 µg hepatitis B vaccine at 0-1-2-6 month than in patients receiving 20 µg hepatitis B vaccine at 0-1-6 month (95%CI: 0.10-0.50), the risk for non/hypo-response was higher in men than in women (OR=3.65, 95%CI: 1.88-7.07), and the risk for non/hypo-response was 2.64 times higher in those without hepatitis B vaccination history than in those with hepatitis B vaccination history (95%CI: 1.10-6.32). Moreover, there were multiplicative interactions between immunization schedule and gender (OR=2.49, 95%CI: 1.24-5.00). Conclusion: The non/hypo-response rate to hepatitis B vaccination was significantly lower in HIV-infected patients receiving 60 µg hepatitis B vaccine at 0-1-2-6 month than in those receiving 20 µg hepatitis B vaccine at 0-1-6 month and 0-1-2-6 month. Gender, vaccination schedule and history of hepatitis B vaccination were the influencing factors of the non/hypo-response to hepatitis B vaccination. There was a multiplicative interaction between vaccination schedule and gender, and men receiving 20 µg hepatitis B vaccines had a higher risk for non/hypo-response to hepatitis B vaccination.
Female ; Follow-Up Studies ; HIV Infections/immunology* ; Hepatitis B/prevention & control* ; Hepatitis B Antibodies ; Hepatitis B Surface Antigens ; Hepatitis B Vaccines/administration & dosage* ; Humans ; Immunization Schedule ; Male

【Objective】 Escherichia coli phage (ECP) and Staphylococcus aureus phage (SAP) isolated from sewage were used as research objects, and their biological characteristics were analyzed to provide new experimental materials for the application of phages. 【Methods】 ECP and SAP were purified and cultured by double-layer agar method. Then a series of biological characteristics of these two phages were preliminarily analyzed by electron microscope observation, optimal multiplicity of infection (MOI) test, one-step growth curve test, temperature, pH, chloroform and ultraviolet sensitivity tests, respectively. 【Results】 The results of biological characteristics showed that ECP and SAP were both virulent phages, belonging to myoviridac family. Their optimal MOI was 10^-1, and they had strong resistance to ultraviolet light. The cleavage volume of ECP was 76.3 PFU/cell, while that of SAP was 8.3 PFU/cell. ECP had a wide range of temperature tolerance and could stably survive at 30-50 ℃, while SAP was more sensitive to temperature and could be completely inactivated at 50 ℃ for 1 h. ECP could maintain a good lysis activity in the range of pH 5-11, while SAP in the range of pH 6-9. ECP had strong resistance to chloroform and was non-membranous phage, while SAP was more sensitive to chloroform and was a membranous phage. 【Conclusion】 ECP and SAP are both virulent phages and have strong resistance to ultraviolet light. The lysability, temperature, pH, and chloroform tolerance of ECP are stronger than those of SAP.

Objective: To evaluate the safety and long-term clinical efficacy of percutaneous coronary intervention (PCI) in patients with in-stent chronic total occlusion (IS-CTO) lesions. Metheds: This is a retrospective analysis. Patients with IS-CTO who underwent PCI in Fuwai hospital from January 2010 to December 2013 were enrolled. A total of 212 patients who met the inclusion criteria were included in the IS-CTO group, 212 matched patients with primary CTO lesions were included in the de novo CTO group. The incidence of complications and the success rate of PCI were compared between the two groups. Successful PCI was defined as successfully implantation of stent(s) at target CTO lesions. The primary endpoint was defined as a composite event of cardiac death and myocardial infarction (MI). Secondary endpoints including PCI success, all-cause death, cardiac death, MI, target vessel related MI, revascularization, target vessel revascularization, heart failure for rehospitalization. The patients were followed up for 5 years after PCI. Results: A total of 424 cases were included. The mean age was (57.8±10.5) years, there were 364 males in this cohort. The left ventricular ejection fraction was significantly lower ((58.7±9.2)% vs. (61.0±7.7)%, P=0.01) and the SYNTAX scores was significantly higher (19.4±8.3 vs. 15.3±10.0, P<0.01) in IS-CTO group than that in de novo CTO group. The proportion of patients with target CTO lesions in left anterior descending artery was significantly higher (42.9% (50/212) vs. 23.6% (91/212), P<0.01) in IS-CTO group than that in de novo CTO group. The rate of successful PCI (71.7% (152/212) vs. 69.8% (148/212), P=0.70) and complication (40.6% (86/212) vs. 36.3% (77/212), P=0.37) was similar between the two groups. The incidence of primary endpoint at 5 years was significantly higher in IS-CTO group (10.8% (23/212) vs. 4.7% (10/212), P=0.02), which was driven by higher incidence of MI (9.0% (19/212) vs. 4.2% (9/212), P=0.05). There were a trend of higher secondary endpoints in IS-CTO group (all P>0.05). Conclusion: The safety and effectiveness of PCI are acceptable in patients with IS-CTO, but the risk of long-term cardiac death and MI is higher among patients with IS-CTO as compared to patients with primary CTO lesions.

To examine levels of M-type phospholipase A2 receptor (PLA2R) and its antibody in the patients with hepatitis B virus-associated membranous nephropathy (HBV-MN), and to explore the correlation of PLA2R with laboratory parameters and pathological characteristics.
 Methods: A total of 49 adult patients with biopsy-proved HBV-MN were enrolled in this study. Levels of anti-PLA2R antibody in serum and PLA2R in renal tissue were detected. Patients were assigned into two groups: a positive PLA2R group and a negative PLA2R group. Differences in laboratory parameters and pathological characteristics were compared between the two groups.
 Results: Of 49 patients with HBV-MN, 17 had positive PLA2R expression in renal tissues. In the positive PLA2R group, 10 patients were positive for serum anti-PLA2R antibody. Patients with positive PLA2R expression in renal tissues showed higher levels of 24 hour urinary protein [(4.6±3.9) g/d], serum HbsAg (70.5%) and renal HbsAg expression (71%), while lower level of serum albumin [(24.1±7.5) g/L] than those of the negative group.
 Conclusion: PLA2R is expressed in the renal tissues and serum anti-PLA2R antibody can be detected in some HBV-MN patients. Positive PLA2R expression in renal tissue might be related to HbsAg deposition in serum and renal tissues. Patients with positive PLA2R expression in renal tissue have more severe glomerular sclerosis.
Adult ; Antibodies ; Autoantibodies ; genetics ; physiology ; Biopsy ; Glomerulonephritis, Membranous ; complications ; etiology ; genetics ; Hepatitis B ; complications ; Hepatitis B Surface Antigens ; adverse effects ; Hepatitis B virus ; Humans ; Kidney ; blood supply ; chemistry ; physiopathology ; Kidney Diseases ; etiology ; genetics ; physiopathology ; Male ; Prognosis ; Proteinuria ; epidemiology ; genetics ; Receptors, Phospholipase A2 ; blood ; physiology ; Serum Albumin ; genetics

Objective: Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear. Methods: A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients' medical records. Multivariable logistic regression models were used to estimate the odds ratio ( Results: Overall, 158 (13.6%) patients were diagnosed with severe illness and 32 (2.7%) had unfavorable outcomes. Hypertension (2.87, 1.30-6.32), type 2 diabetes (T2DM) (3.57, 2.32-5.49), cardiovascular disease (CVD) (3.78, 1.81-7.89), fatty liver disease (7.53, 1.96-28.96), hyperlipidemia (2.15, 1.26-3.67), other lung diseases (6.00, 3.01-11.96), and electrolyte imbalance (10.40, 3.00-26.10) were independently linked to increased odds of being severely ill. T2DM (6.07, 2.89-12.75), CVD (8.47, 6.03-11.89), and electrolyte imbalance (19.44, 11.47-32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission (5.46, 3.25-9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes (6.58, 1.46-29.64) within two weeks. Conclusion Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.
Adult ; Aged ; COVID-19/virology* ; China/epidemiology* ; Comorbidity ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome